Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide.

Weihong Pan1, Beka Solomon, Lawrence M Maness

  • 1Veterans Affairs Medical Center and Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA. wpan@tulane.edu

Experimental Biology and Medicine (Maywood, N.J.)
|August 23, 2002
PubMed
Summary

Antibodies targeting amyloid-beta (Abeta) peptides can reduce their entry into the brain. This study shows that specific antibodies effectively block Abeta passage across the blood-brain barrier, potentially preventing Alzheimer's disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beneficial effect of lactate in neurodegenerative diseases: Association with downregulation of C-X-C motif chemokine receptor 4 signaling.

Neural regeneration research·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Amyloid-β is NOT only the most promising target for Alzheimer's disease.

Neural regeneration research·2024
Same author

Bone marrow-derived microglia confer neuroprotection to a mouse model of amyotrophic lateral sclerosis.

Neural regeneration research·2024
Same author

Reduced Serum Levels of Soluble Interleukin-15 Receptor α in Schizophrenia and Its Relationship to the Excited Phenotype.

Frontiers in psychiatry·2022
Same author

Estrogen can abolish oxytocin-induced spinal anti-hyperalgesia.

Psychoneuroendocrinology·2021

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Amyloid-beta (Abeta) peptides are implicated in Alzheimer's disease and amyloid angiopathy.
  • Abeta's entry into the central nervous system (CNS) across the blood-brain barrier (BBB) may contribute to plaque formation.
  • Therapeutic antibodies targeting Abeta are being developed for Alzheimer's disease prevention and treatment.

Purpose of the Study:

  • To investigate whether therapeutic antibodies can block the influx of Abeta into the brain at the BBB level.
  • To assess the efficacy of specific anti-Abeta antibodies in reducing Abeta accumulation in brain parenchyma.

Main Methods:

  • Ex-vivo incubation of radiolabeled Abeta (125I-Abeta(1-40)) with anti-Abeta antibodies (mAb3D6 and mAbmc1).
  • Assessment of Abeta influx into the brain following intravenous injection in vivo.

Related Experiment Videos

  • In-situ brain perfusion studies to confirm antibody specificity and blocking effects at the BBB.

    • Main Results:

    • The antibody mAb3D6 significantly reduced the blood-to-brain influx of Abeta after intravenous administration.
    • mAb3D6 also led to a significant decrease in Abeta accumulation within the brain parenchyma.
    • The antibody mAbmc1, tested via in-situ brain perfusion, similarly demonstrated a significant reduction in Abeta influx into the brain.

    Conclusions:

    • Effective antibodies against Abeta can successfully reduce the influx of Abeta(1-40) across the blood-brain barrier.
    • These findings support the potential of anti-Abeta antibodies as a therapeutic strategy to limit Abeta deposition in the brain for Alzheimer's disease.
    • Antibody-mediated blocking of Abeta transport at the BBB represents a viable approach to mitigate CNS amyloid pathology.